1. Home
  2. NYXH vs ATYR Comparison

NYXH vs ATYR Comparison

Compare NYXH & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NYXH
  • ATYR
  • Stock Information
  • Founded
  • NYXH 2009
  • ATYR 2005
  • Country
  • NYXH Belgium
  • ATYR United States
  • Employees
  • NYXH N/A
  • ATYR N/A
  • Industry
  • NYXH Medical/Dental Instruments
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • NYXH Health Care
  • ATYR Health Care
  • Exchange
  • NYXH Nasdaq
  • ATYR Nasdaq
  • Market Cap
  • NYXH 261.1M
  • ATYR 228.1M
  • IPO Year
  • NYXH 2021
  • ATYR 2015
  • Fundamental
  • Price
  • NYXH $7.94
  • ATYR $3.12
  • Analyst Decision
  • NYXH Strong Buy
  • ATYR Strong Buy
  • Analyst Count
  • NYXH 5
  • ATYR 4
  • Target Price
  • NYXH $17.00
  • ATYR $19.25
  • AVG Volume (30 Days)
  • NYXH 38.9K
  • ATYR 763.0K
  • Earning Date
  • NYXH 11-06-2024
  • ATYR 11-07-2024
  • Dividend Yield
  • NYXH N/A
  • ATYR N/A
  • EPS Growth
  • NYXH N/A
  • ATYR N/A
  • EPS
  • NYXH N/A
  • ATYR N/A
  • Revenue
  • NYXH $5,668,079.00
  • ATYR $235,000.00
  • Revenue This Year
  • NYXH $37.10
  • ATYR N/A
  • Revenue Next Year
  • NYXH $418.12
  • ATYR $1,290.73
  • P/E Ratio
  • NYXH N/A
  • ATYR N/A
  • Revenue Growth
  • NYXH 32.65
  • ATYR N/A
  • 52 Week Low
  • NYXH $4.00
  • ATYR $1.28
  • 52 Week High
  • NYXH $20.00
  • ATYR $3.80
  • Technical
  • Relative Strength Index (RSI)
  • NYXH 42.46
  • ATYR 48.52
  • Support Level
  • NYXH $7.86
  • ATYR $2.98
  • Resistance Level
  • NYXH $8.81
  • ATYR $3.26
  • Average True Range (ATR)
  • NYXH 0.48
  • ATYR 0.23
  • MACD
  • NYXH 0.06
  • ATYR -0.05
  • Stochastic Oscillator
  • NYXH 43.87
  • ATYR 17.50

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

Share on Social Networks: